Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18353076 | 0.89 | AAK1 (0.37) | AAK1RBP4 | |
| SCHEMBL16947094 | 0.89 | AAK1 (0.37) | AAK1RBP4 | |
| SCHEMBL16947089 | 0.78 | KDM4E (0.39) | — | |
| SCHEMBL18352908 | 0.78 | KDM4E (0.39) | — | |
| SCHEMBL18352379 | 0.75 | SCN9A (0.40) | AAK1 | |
| SCHEMBL16935982 | 0.72 | SCN9A (0.38) | AAK1 | |
| SCHEMBL30092492 | 0.72 | SCN9A (0.38) | AAK1 | |
| SCHEMBL16947088 | 0.72 | RBP4 (0.39) | RBP4 | |
| SCHEMBL21941640 | 0.71 | SCN9A (0.40) | — | |
| SCHEMBL18357995 | 0.71 | RBP4 (0.33) | RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | AAK1 86/4885RBP4 4739/4885 |
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | MAP3K20, LCK, MAP3K1 | AAK1 86/4885RBP4 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.